Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL2205229 | 0.80 | SLC7A5 (0.50) | PARP1MEN1KMT2ASLC7A5ALDH1A1 | |
| Quinoline SCHEMBL4747553 | 0.79 | ALDH1A1 (0.55) | NPC1MEN1KMT2ASLC7A5ADORA2A | |
| SCHEMBL20889269 | 0.78 | PARP1 (0.46) | PARP1PSMD14MEN1KMT2ACA1 | |
| SCHEMBL19682364 | 0.78 | PARP1 (0.46) | PARP1PSMD14MEN1KMT2ACA1 | |
| Valine SCHEMBL20476530 | 0.76 | SLC7A5 (0.48) | SLC7A5ALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL196509 | 0.76 | LMNA (0.64) | PARP1PSMD14NPC1MEN1PKM | |
| Oxyquinoline SCHEMBL27982208 | 0.75 | METAP2 (0.66) | PARP1PSMD14KMT2ACA1CA2 | |
| Water SCHEMBL28285432 | 0.74 | LMNA (0.61) | PARP1PSMD14NPC1MEN1PKM | |
| SCHEMBL28750659 | 0.73 | TDP1 (0.63) | NPC1MEN1KMT2AMAPK1TDP1 | |
| SCHEMBL28750660 | 0.73 | TDP1 (0.63) | NPC1MEN1KMT2AMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9974782-B2 | Phosphodiesterase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170216275-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-03 | — | — | US | disclosed |
| US-9422242-B2 | Phosphodiesterase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150080394-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | COLUMBIA UNIVERSITY (US) | 2015-03-19 | — | — | US | disclosed |
| EP-2379076-B1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | UNIV COLUMBIA (US) | 2014-11-12 | — | — | EP | disclosed |
| US-8697875-B2 | Phosphodiesterase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-04-15 | — | — | US | disclosed |
| US-20120076732-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-03-29 | — | — | US | disclosed |
| EP-2379076-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010074783-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120076732-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, PDE5A, PDE4A | PARP1 1664/4885PSMD14 1827/4885NPC1 2129/4885 |
| US-20150080394-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, PDE5A, PDE4A | PARP1 1664/4885PSMD14 1827/4885NPC1 2129/4885 |
| US-20170216275-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, PDE5A, PDE4A | PARP1 1664/4885PSMD14 1827/4885NPC1 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.